An analysis of the FINEARTS-HF trial, which showed finerenone's benefits in heart failure outcomes, shows no significant ...

Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...

Research Triangle Park (RTP) is widely recognized as one of the foremost innovation hubs in the United States. Situated ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American ...

The growth of the Chronic Hepatitis B Virus Testing market can be attributed to several key factors, including significant ...

On Oct. 26, 1944, after four days of furious fighting, the World War II battle of Leyte Gulf, largest air-naval clash in ...

The growth of the DEE treatment market can be attributed to the increasing prevalence of developmental and epileptic ...

Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...